Management of WDHA Syndrome

Immediate Stabilization and Rehydration

Aggressive intravenous fluid and electrolyte replacement is the critical first step and may dramatically improve the clinical condition, according to the European Society of Gastrointestinal Endoscopy 1, 2
Correct hypokalemia aggressively, as patients typically have profound potassium depletion from massive diarrheal losses, as recommended by the European Society of Gastrointestinal Endoscopy 1, 2
Monitor and correct hypomagnesemia, as magnesium deficiency impairs potassium transport systems and causes refractory hypokalemia, as stated by the European Society of Gastrointestinal Endoscopy 3, 4
Document secretory diarrhea volume, which is typically >3 L/24 hours, as noted by the European Society of Gastrointestinal Endoscopy 1, 2

Somatostatin analogues produce dramatic symptomatic relief and are the cornerstone of medical therapy for WDHA syndrome, according to the European Society of Gastrointestinal Endoscopy 1, 2
Start subcutaneous octreotide at 50-100 mcg twice or three times daily, with diarrhea often ceasing within hours of the first dose, as recommended by the European Society of Gastrointestinal Endoscopy 1, 2
Transition to long-acting somatostatin analogues after initial stabilization with short-acting octreotide, as stated by the European Society of Gastrointestinal Endoscopy 1, 2
Titrate the dose against VIP levels, with normalization of VIP being the therapeutic target, as noted by the European Society of Gastrointestinal Endoscopy 1, 2

Perform somatostatin receptor scintigraphy as the most sensitive imaging modality for tumor localization, as recommended by the European Association of Nuclear Medicine 5
Use endoscopic ultrasound, CT, or MRI to identify pancreatic tumors or extra-pancreatic sources, as stated by the European Association of Nuclear Medicine 5
Screen for multiple endocrine neoplasia type 1 with family history and genetic testing if indicated, as recommended by the National Comprehensive Cancer Network 6

Provide perioperative octreotide coverage starting 12 hours before surgery and continuing 48 hours post-operatively to prevent crisis, as recommended by the European Society of Gastrointestinal Endoscopy 1, 2

Continue long-acting somatostatin analogues indefinitely, with dose escalation often needed over time, as stated by the European Society of Gastrointestinal Endoscopy 1, 2
Consider peptide receptor radionuclide therapy for well-differentiated tumors with positive somatostatin receptor imaging, as recommended by the European Association of Nuclear Medicine 5
Monitor with serial VIP levels and imaging to assess disease progression, as noted by the European Society of Gastrointestinal Endoscopy 1, 2

Do not delay somatostatin analogue therapy while awaiting diagnostic confirmation, as the syndrome is life-threatening and responds dramatically to treatment, as stated by the European Society of Gastrointestinal Endoscopy 1, 2
Do not treat hypokalemia without correcting hypomagnesemia first, as magnesium-deficient hypokalemia is refractory to potassium replacement alone, as recommended by the European Society of Gastrointestinal Endoscopy 3, 4